- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00030342
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
A Phase I/II Study Of Interleukin-12-Primed Activated T Cells In Combination With 5FU, GM-CSF And Interferon Alfa-2b In Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of biological therapy combined with chemotherapy in treating patients who have metastatic kidney cancer or colorectal cancer.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
- Determine the safety of a repeat course of interleukin-12-primed activated T cells (12ATC) in combination with fluorouracil, sargramostim (GM-CSF), and interferon alfa-2b in patients with metastatic renal cell or colorectal carcinoma.
- Determine the clinical responses of patients treated with this regimen.
- Determine the efficacy of 12ATC in these patients.
- Determine whether there are changes in immunologic parameters related to 12ATC as measured by lymphocyte phenotype and cytokine secretion in these patients.
- Determine the correlation between clinical responses in patients treated with this regimen and in vitro immune functions of lymphocytes.
OUTLINE: Patients are stratified according to disease type (renal cell carcinoma vs colorectal carcinoma).
Patients receive sargramostim (GM-CSF) subcutaneously (SC) daily on days 1-5 and then undergo collection of autologous peripheral blood mononuclear cells (PBMC) on days 6 and 7 of week 1. The PBMC are treated ex vivo to form interleukin-12-primed activated T cells (12ATC).
Patients receive fluorouracil IV over 24 hours on day 6 of week 2 and interferon alfa-2b SC and GM-CSF SC 3 times weekly on weeks 3-5. Patients receive 12ATC IV over 15-30 minutes twice weekly and interferon alfa-2b SC (at least 24 hours after 12ATC infusion) once weekly on weeks 6-8. Patients with complete or partial response or stable disease at 3 weeks after the last 12ATC infusion may receive an additional 8-week course as above.
Patients are followed every 2-3 months for 1 year and then every 6 months for 2 years or at any time when the physical examination or symptoms are suspicious for tumor progression.
PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study within 2-3 years.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53215
- Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed metastatic renal cell carcinoma or colorectal carcinoma, meeting 1 of the following criteria:
- Obtained no benefit from prior standard or salvage therapy
- Ineligible for standard therapy because of concurrent illness
- Declined standard therapy
At least 1 site of measurable disease that can be measured in at least 1 dimension
- At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan
- No untreated or unstable, treated brain metastasis
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC at least 4,000/mm^3
- Granulocyte count at least 2,000/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
- No coagulation disorders
Hepatic:
- Bilirubin no greater than 2.5 mg/dL*
- ALT/AST less than 3 times upper limit of normal*
- PT no greater than 1.5 times control (unless therapeutically anticoagulated)
- PTT less than 1.5 times control (unless therapeutically anticoagulated) NOTE: *Patients whose cancer has led to values that do not fall within the above ranges may be eligible at the discretion of the investigators
Renal:
- Creatinine no greater than 2.0 mg/dL* NOTE: *Patients whose cancer has led to values that do not fall within the above range may be eligible at the discretion of the investigators
Cardiovascular:
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No thrombophlebitis
Pulmonary:
- FEV_1 and FVC at least 65% predicted
- No uncontrolled pulmonary embolism
Other:
- No other malignancy within the past 5 years except resected basal cell skin cancer or carcinoma in situ of the cervix
- No prior allergic reactions attributed to compounds of similar chemical or biologic composition to interleukin-12-primed activated T cells or other study agents
- No active autoimmune disease
- No uncontrolled thyroid abnormalities
- No ongoing or active infection
- No other uncontrolled concurrent illness
- No psychiatric illness or social situations that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for up to 2 years after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- More than 4 weeks since prior immunotherapy
Chemotherapy:
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy:
- At least 4 weeks since prior steroid therapy or steroid-containing compounds
- At least 2 weeks since prior topical or inhaled steroids
Radiotherapy:
- More than 4 weeks since prior radiotherapy and recovered
Surgery:
- More than 4 weeks since prior major surgery
Other:
- No other concurrent investigational agents
- No other concurrent commercial anticancer agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Överlevnad mätt med Kaplan-Meier-metoden vid 5 år
|
Response as measured by RECIST guidelines and Kaplan-Meier method at 5 years
|
Safety as measured by NCI common toxicity table at study completion
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: John P. Hanson, MD, St. Luke's Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urologiska neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Njursjukdomar
- Urologiska sjukdomar
- Adenocarcinom
- Carcinom
- Neoplasmer, körtel och epitel
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Kolonsjukdomar
- Tarmsjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Neoplasmer i njurarna
- Karcinom, njurcell
- Kolorektala neoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Interferoner
- Interferon-alfa
- Fluorouracil
- Sargramostim
Andra studie-ID-nummer
- STLMC-IMM-0104
- CDR0000069153 (Registeridentifierare: PDQ (Physician Data Query))
- STLMC-L-01108
- NCI-V01-1686
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Njurcancer
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Medical University of ViennaAvslutadSekundär hyperparatyreos | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NjurersättningÖsterrike
-
Hans BahlmannLinkoeping UniversityRekryteringNjurcancer | Uretercancer | Andra specificerade störningar av njure och urinledare | Benign Neoplasm av Ureter | Calculus of Kidney and Ureter | Ureterisk reflux | Medfödd ureteranomali | Benign renal neoplasmSverige
Kliniska prövningar på rekombinant interferon alfa
-
Catholic University of the Sacred HeartSOFAR S.p.A.OkändGodartade, premaligna och maligna gynekologiska sjukdomar begränsade till bäckenetItalien
-
Xiangya Hospital of Central South UniversityOkänd
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekrytering
-
Peking University Third HospitalRekryteringSköldkörtelögonsjukdomKina
-
University of EdinburghRekryteringAortastenos | Carcinoid syndrom | Kemoterapiinducerad systolisk dysfunktionStorbritannien
-
Huashan HospitalRekryteringNeoplasmer | PositronemissionstomografiKina
-
UMC UtrechtHar inte rekryterat ännuMetastaserande kolorektal cancer | Metastaserande cancer i levern
-
Sichuan Provincial People's HospitalRekryteringAldosteronproducerande adenomKina
-
Institute of Liver and Biliary Sciences, IndiaAvslutadAkut leversvikt | Akut vid kronisk leversviktIndien